Home / Success stories /Abbott Laboratories

Abbott Laboratories

A global healthcare giant relies on us for end-to-end test automation

Slogan

Learn how we supported Abbott Laboratories, the global leader in diabetes care, to deliver digital products which improve patient outcomes and lower systemic healthcare costs

Our Client

Abbott’s FreeStyle Libre system is the number one sensor-based glucose monitoring system used worldwide. A core application of the system is Libreview, a secure, cloud-based diabetes management system that gives healthcare professionals and patients clear, easy-to-understand reports from compatible FreeStyle glucose monitoring devices.

The FreeStyle Libre ecosystem of digital tools includes smartphone apps such as FreeStyle and LibreLinkUp, and a cloud-based data system called LibreView5 that allow users, caregivers, and doctors to access real-time glucose data and actionable information which guide the right treatment decisions.

By capturing and reporting data in real time, clinical decisions can be made much earlier, lowering the risks of the patient entering the primary or emergency care systems through better management of their condition.

With a sophisticated healthcare application, relied upon by a global user base, and ambitious release schedule, how did Abbott Laboratories stay on top of their commitment to delivering high quality products to their customers?

Industry

Healthcare

20

Engineers

US

Country

Since 2019

Cooperation

Learn how we help

About the project

Abbott Laboratories is an American multinational medical devices and health care company, spanning pharmaceuticals, medical devices, diagnostic assays and nutritional products. With over 100,000 employees, global turnover is in excess of $40bn, with their glucose management FreeStyle product line representing 9% of total revenue.

The growth in Diabetes Care revenue in 2020 and 2021 was mostly driven by the continued growth of FreeStyle Libre, Abbott’s continuous glucose monitoring system, internationally and in the U.S. In 2021, FreeStyle Libre sales reached $3.7 billion, which reflected a 36.8 percent increase compared to 2020, excluding the effect of foreign exchange. In 2020 its sales were $2.6 billion, which reflected a 42.6 percent increase, excluding the effect of foreign exchange, compared to 2019 when the sales totalled $1.8 billion.

Abbott’s third-quarter 2022 report shows worldwide sales of $10.4 billion in the corresponding period, raise of its full-year 2022 EPS guidance, and a strengthening of its position on the market with a new-gen FreeStyle Libre 3 system automatically delivering up-to-minute glucose readings via the smallest and tiniest in the world wearable sensor

Their success

The deployment of our automation testing capability helped Abbott grow their innovative and convenient Diabetes monitoring solution to a global community of physicians and their patients. Today, with a highly stable product with no localisation issues or critical bugs, FreeStyle Libre is actively used by over 4 million users who rely on the service to provide timely reporting of their blood glucose.

We have been working on Libreview since the end of 2019. With an initial engagement of 5 automation testing engineers and a QA lead, Abbott requested a further 6 QA engineers based on the quality of service they received from us.

As an ambitious growth business, including new pushes into Taiwan, Slovakia and Egypt in 2022, Abbott are continually upscaling our team to cover its growing QA needs. We believe this is proof of our status as a reliable QA partner, treating the project as a development effort rather than a testing effort, anticipating the next steps and improvements, quickly responding to changes, proactively taking on current problems and addressing future issues. Our cooperation means that over 20 engineers now provide the QA service to Abbott.

Our engagement

We were engaged to design and implement the automated testing of Libreview and manage the ongoing optimisation of the automation platform. The goals were simple: allow Abbott to release a complex product more frequently and more thoroughly, and provide time back to the team to work on higher value challenges.

Through design and implementation of the test infrastructure, we significant optimised the QA process, reducing from 7 days to 1 day the time taken to perform a smoke test. We further reduced the amount of time required to execute smoke testing of individual countries by over 85%. The current test suite involves over 1700 tests supporting 4 web browsers.

With a keyword-driven testing methodology and a focus on performance and flexibility, our testing platform allows all team members to clearly and easily understand tests and the implementation of specific logic, providing an opportunity to choose and run tests based on individual preferences and parameters.

The move to automation provided substantial value to Abbott, freeing up time for the internal manual QA team to focus on testing new features, developing new test cases and keeping existing ones up to date. Our efforts drove up the level of test coverage of Abbott products, resulting in one happy customer!

Client Success

+11

Lviv

+24

Kharkiv

+15

Kyiv

+48

Poland

+12

Germany

+21

Lithuania

+19

Latvia

+12

Slovakia

Greece

Portugal

Netherlands

+15

Estonia

+21

Czech Republic

Andorra

With a pan European talent pool, Devico brings together the continents best talent and makes them available for you